GlassScriptPhysician profile
Ashkan Pirouz
NPI 1942489356
$9,210.31
in general payments reported to CMS, 2019-2025
21 companies · $1,105 in 2025
The $1,105 reported for 2025 was more than what 75% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,124 · 2020: $454 · 2021: $604 · 2022: $739 · 2023: $1,229 · 2024: $3,955 · 2025: $1,105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,174 · Consulting Fee: $2,115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,173.77 |
| Consulting Fee | $2,115.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $3,282.05 | 2019-2025 | Vabysmo, Susvimo |
| Regeneron Healthcare Solutions, INC. | $1,714.93 | 2019-2025 | Eylea Hd, Eylea |
| Alcon Vision LLC | $1,233.36 | 2019-2024 | Constellation |
| Apellis Pharmaceuticals, INC. | $770.74 | 2022-2025 | Syfovre |
| Abbvie INC. | $392.83 | 2022-2025 | |
| Regeneron Pharmaceuticals, INC. | $337.00 | 2023-2025 | Eylea Hd, Eylea |
| Astellas Pharma US INC | $310.45 | 2023-2025 | Izervay |
| Ani Pharmaceuticals, INC. | $294.13 | 2024-2025 | Purified Cortrophin Gel, Iluvien, Yutiq |
| Allergan, INC. | $190.68 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $171.42 | 2019-2022 | |
| Genentech, INC. | $135.45 | 2024 | Evrysdi, Vabysmo, Susvimo |
| Coherus Oncology, INC. | $102.13 | 2022-2024 | |
| Astellas Pharma Global Development | $80.20 | 2024-2025 | Izervay |
| Bausch & Lomb Americas INC. | $58.19 | 2022-2025 | Xipere |
| Sandoz INC. | $48.18 | 2024 | Cimerli |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $40.81 | 2019-2024 | Yutiq, Iluvien |
| Horizon Therapeutics Plc | $18.49 | 2022 | |
| Ocular Therapeutix, INC. | $15.33 | 2025 | Dextenza |
| Biogen, INC. | $13.94 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashkan Pirouz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.